New Study Shows Increases in RSV Hospitalization among High-Risk Preterm Infants
October 05 2016 - 7:00AM
Business Wire
New Respiratory Syncytial Virus (RSV)
Hospitalization Data from 2014-2015 RSV season compared to
2013-2014 RSV season presented at AMCP Nexus 2016
AstraZeneca today announced new data demonstrating that
respiratory syncytial virus hospitalization (RSVH) rates increased
significantly during the 2014-2015 RSV season among US infants
<3 months of age born at 29-34 weeks gestational age (wGA), as
compared to the 2013-2014 season.1 RSV is a contagious, seasonal
respiratory virus that can lead to a serious lung infection and
hospitalization in high-risk babies, particularly preterm
infants.2,3,4 These data are based on data from over 2.2 million US
infants and represent the first and only analysis conducted using
national US Medicaid and Commercial insurance claims databases to
further understand the changes in both immunoprophylaxis (IP)
utilization and RSVH rates. This research was presented as a poster
(poster number J14) at the annual Academy of Managed Care Pharmacy
(AMCP) Nexus meeting in National Harbor, MD.
Results showed that among <3 months old infants who were born
at 29-34 wGA, RSVH rates increased by 170% and 40% within the
commercial and Medicaid populations, respectively, during the
2014-2015 season when compared to the prior season.1
- RSVH rates for <6 months old infants
who were born at 29-34 wGA were 2-7 times higher than RSVH rates
for <6 months old infants who were born full term in the
2014-2015 season.1
Dr. Leonard Krilov, pediatric infectious disease specialist,
Winthrop-University Hospital, said: “RSV disease, a leading cause
of hospitalization for babies in their first year of life in the
United States, can be especially severe during the first few months
of life, creating a significant burden on individual infants, their
families and the health care systems who treat these vulnerable
patients. These data emphasize the importance and risk of this
disease in infants.”
IP use during the 2014-2015 season decreased by 45-94% and
65-95% among commercial and Medicaid populations, respectively,
versus the 2013-2014 season.1 The results are based on data that
evaluate independent changes in RSVH rates and IP utilization
preceding and following the 2014 American Academy of Pediatrics
guidance.
RSVH rates and increases of RSVH rates in the 2014-2015 RSV
season were highest during the first three months in life for
infants born at earlier gestational ages.1 Dr. Krilov said: “These
data confirm that preterm infants – specifically those born at
29-34 wGA – are at an increased risk for hospitalization for severe
RSV disease. Contributing new data to the scientific conversations
among key industry stakeholders allows us to further the
conversation around severe RSV disease both at this meeting and for
future RSV seasons to come.”
NOTES TO EDITORS
About The Poster Presented at AMCP Nexus 2016 (poster number
J14)
These data are comprised of an analysis of both RSVH rates and
IP utilization during the 2014-2015 RSV season versus the 2013-2014
RSV season. The study evaluated 1.7 million Medicaid and 1.5
million Commercial births from each respective database to assess
outpatient IP use and RSVH occurrences between November 2014 and
March 2015. 1.2 million Medicaid and 1.0 million commercial preterm
and full-term infants without chronic lung disease or congenital
heart disease were selected from the databases using DRG and
ICD-9-CM codes. RSVH rates were calculated per 100 infant-seasons
with Medicaid and Commercial database infants weighted by
prevalence of US births. To adjust for seasonal variation, rate
ratios for preterm infants were calculated relative to full-term
infants.
About RSV
RSV is a contagious, seasonal respiratory virus that nearly all
children will contract by the age of two and most will recover from
within 1-2 weeks.2,3,4 In certain high-risk babies, however, RSV
can lead to a serious lung infection and hospitalization.6,7
Preterm infants are at increased risk of developing severe RSV
disease because their lung volume is significantly less than that
of full-term infants, and their airways are smaller and narrower
than those of a baby born at term.8
About Academy of Managed Care Pharmacy Nexus 2016
Meeting
The Academy of Managed Care Pharmacy (AMCP) Nexus 2016 Meeting
is being held from Monday, October 3rd to Thursday, October 6th in
National Harbor, MD. AMCP Nexus 2016 provides an educational space
for managed care professionals to discuss developments and issues
in the managed care pharmacy space.
About AstraZeneca
AstraZeneca is a global, science-led biopharmaceutical company
that focuses on the discovery, development and commercialization of
prescription medicines, primarily for the treatment of diseases in
three therapy areas – Respiratory and Autoimmunity, Cardiovascular
and Metabolic Diseases, and Oncology. The company is also active in
inflammation, infection and neuroscience through numerous
collaborations. AstraZeneca operates in over 100 countries and its
innovative medicines are used by millions of patients worldwide.
For more information please visit: www.astrazeneca-us.com.
References
- McLaurin K, Pavilack M, Krilov L,
Diakun D, Wade S, Farr A. Poster Number J14. Poster presented at
Academy of Managed Care Pharmacy (AMCP) Nexus 2016 Meeting, October
3-6 2016.
- Glezen WP, Taber LJ, Frank AL, Kasel
JA. Risk of Primary Infection and Reinfection with Respiratory
Syncytial Virus. Am J Dis Child. 1986; 140:543-546.
- Centers for Disease Control and
Prevention. Infection and Incidence.
http://www.cdc.gov/rsv/about/infection.html. Accessed June 26,
2015.
- Hall CB, Weinberg GA, Iwane MK, et al.
The Burden of Respiratory Syncytial Virus Infection in Young
Children. N Engl J Med. 2009; 360:588-598.
- Leader S, Kohlhase K. Respiratory
syncytial virus-coded pediatric hospitalizations, 1997 to 1999.
Pediatr Infect Dis J. 2002; 21: 629-632.
- Boyce TG, et al. Rates of
hospitalizations for respiratory syncytial virus infection among
children in Medicaid. J Pediatr. 2000; 137:865-70.
- Centers for Disease Control and
Prevention. Preterm Birth.
http://www.cdc.gov/reproductivehealth/maternalinfanthealth/pretermbirth.htm.
Accessed June 26, 2015.
- Langston C, Kida K, Reed M, Thurlbeck
WM. Human lung growth in late gestation and in the neonate. Am Rev
Respir Dis. 1984; 129:607-613.
View source
version on businesswire.com: http://www.businesswire.com/news/home/20161005005181/en/
AstraZenecaMichele Meixell, +1 302-885-2677orAbigail Bozarth, +1
302-885-2677
AstraZeneca (NYSE:AZN)
Historical Stock Chart
From Aug 2024 to Sep 2024
AstraZeneca (NYSE:AZN)
Historical Stock Chart
From Sep 2023 to Sep 2024